BRPI0503488A - agente de tratamento para sìndrome de intestino irritável com diarréia predominante - Google Patents

agente de tratamento para sìndrome de intestino irritável com diarréia predominante

Info

Publication number
BRPI0503488A
BRPI0503488A BRPI0503488-4A BRPI0503488A BRPI0503488A BR PI0503488 A BRPI0503488 A BR PI0503488A BR PI0503488 A BRPI0503488 A BR PI0503488A BR PI0503488 A BRPI0503488 A BR PI0503488A
Authority
BR
Brazil
Prior art keywords
treatment agent
bowel syndrome
irritable bowel
diarrhea
predominant diarrhea
Prior art date
Application number
BRPI0503488-4A
Other languages
English (en)
Inventor
Akito Nishida
Akira Niwa
Yutaka Atsuta
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/JP2004/000896 external-priority patent/WO2004066998A1/ja
Priority claimed from PCT/JP2004/006657 external-priority patent/WO2005073220A1/ja
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of BRPI0503488A publication Critical patent/BRPI0503488A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"AGENTE DE TRATAMENTO PARA SìNDROME DE INTESTINO IRRITáVEL COM DIARRéIA PREDOMINANTE". Composição farmacêutica para a terapia de síndrome de intestino irritável com diarréia em pacientes masculinos e femininos, contendo de 0,001 a 0,05 mg de cloridrato de ramosetron como uma dose diária ou uma quantidade molar equivalente de ramosetron ou seu outro sal farmaceuticamente aceitável como um ingrediente ativo.
BRPI0503488-4A 2004-01-30 2005-01-27 agente de tratamento para sìndrome de intestino irritável com diarréia predominante BRPI0503488A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/JP2004/000896 WO2004066998A1 (ja) 2003-01-31 2004-01-30 安定な経口用固形医薬組成物
PCT/JP2004/006657 WO2005073220A1 (ja) 2004-01-30 2004-05-12 下痢型過敏性腸症候群治療剤
PCT/JP2005/001549 WO2005072730A1 (ja) 2004-01-30 2005-01-27 下痢型過敏性腸症候群治療剤

Publications (1)

Publication Number Publication Date
BRPI0503488A true BRPI0503488A (pt) 2006-03-07

Family

ID=34829390

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0503488-4A BRPI0503488A (pt) 2004-01-30 2005-01-27 agente de tratamento para sìndrome de intestino irritável com diarréia predominante

Country Status (11)

Country Link
EP (1) EP1559446B1 (pt)
AT (1) ATE516061T1 (pt)
AU (1) AU2005209112B2 (pt)
BR (1) BRPI0503488A (pt)
CA (1) CA2516433C (pt)
MX (1) MXPA05009025A (pt)
NO (1) NO20054002L (pt)
NZ (1) NZ541656A (pt)
PL (1) PL380448A1 (pt)
RU (1) RU2314808C2 (pt)
WO (1) WO2005072730A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0381422B1 (en) * 1989-02-02 1996-10-23 Yamanouchi Pharmaceutical Co. Ltd. Tetrahydrobenzimidazole derivatives
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
WO1999064401A2 (en) * 1998-06-12 1999-12-16 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Imidazolyl derivatives and their use as somatostatin receptor ligands
AR028970A1 (es) * 2000-07-26 2003-05-28 Solvay Pharm Gmbh USO DE CILANSETRON O DE SUS SALES POR ADICIoN DE A CIDOS Y/O SOLVATOS FARMACOLoGICAMENTE COMPATIBLES PARA LA OBTENCIoN DE PREPARADOS FARMACEUTICOS PARA EL TRATAMIENTO Y/O LA PROFILAXIS DEL SíNDROME DEL INTESTINO IRRITABLE
US6566369B2 (en) * 2000-07-26 2003-05-20 Solvay Pharmaceuticals Gmbh Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients

Also Published As

Publication number Publication date
EP1559446B1 (en) 2011-07-13
NZ541656A (en) 2008-05-30
MXPA05009025A (es) 2006-04-27
RU2314808C2 (ru) 2008-01-20
RU2005127333A (ru) 2006-07-10
CA2516433A1 (en) 2005-08-11
AU2005209112A1 (en) 2005-08-11
ATE516061T1 (de) 2011-07-15
WO2005072730A1 (ja) 2005-08-11
NO20054002L (no) 2005-10-26
HK1090561A1 (zh) 2006-12-29
AU2005209112B2 (en) 2007-07-05
EP1559446A1 (en) 2005-08-03
NO20054002D0 (no) 2005-08-29
PL380448A1 (pl) 2007-02-05
CA2516433C (en) 2009-06-02

Similar Documents

Publication Publication Date Title
NO20014519D0 (no) Apomorfin- og sildenafilpreparat
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
MXPA05004778A (es) Metodos de uso y composiciones que contienen compuestos inmunomoduladores para el tratamiento y manejo de enfermedades mieloproliferativas.
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
EP4442321A3 (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
AR040248A1 (es) Farmaco para el tratamiento de la vejiga hiperactiva
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
TNSN07474A1 (en) Dosage regimen for prasugrel
SI1677806T1 (sl) Postopki za zdravljenje akutnega in s preobremenitvijo povzročenega zvina in natega z uporabo hialuronske kisline
BRPI0510895A (pt) formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t
RU2007119067A (ru) Средство для лечения синдрома раздраженного кишечника с преобладанием диареи
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
AR061233A1 (es) Formulacion de liberacion prolongada de naltrexona
NZ595798A (en) Ectoparasiticidal methods and formulations
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.
BRPI0410374A (pt) composição farmacêutica que compreende valsartano
MX2010006310A (es) O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor.
WO2007144889A3 (en) Treatment of neurofibromatosis

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.